Upstream Biosciences CEO to Unveil Promising New Approach to Treating Sleeping Sickness at International Trypanosomiasis Conference



    
    - Keynote Address to Highlight Upstream's Drug Candidates That Have
    Demonstrated Promising In Vitro Activity Against "Sleeping Sickness" and
    Other Parasitic Diseases -

    - Need for Improved Therapies Highlighted at International Scientific
    Council for Trypanosomiasis Research and Control (ISCTRC) Conference in
    Africa -
    

    VANCOUVER, British Columbia, Oct. 2 /CNW/ -- Upstream Biosciences Inc.
(OTC Bulletin Board:   UPBS) today announced that its Chief Executive Officer,
Joel L. Bellenson, will unveil Upstream's promising new drug candidates in a
keynote address to the International Scientific Council for Trypanosomiasis
Research and Control (ISCTRC) conference being held in Angola from October 1
to 5, 2007.  Trypanosomiasis is the medical term for the disease known as
African sleeping sickness.  According to the World Health Organization (WHO),
an estimated 60 million people in sub-Saharan Africa are at risk of
contracting this devastating condition spread by the tsetse fly. Sleeping
sickness also afflicts cattle and has been a major obstacle to the success of
cattle raising in the region, causing an estimated $4.5 billion annually in
lost food and agricultural revenues.  The disease is fatal if untreated but
current therapies for trypanosomiasis are expensive, toxic and often
ineffective. The ISCTRC conference brings together African Union member
states, researchers, and field workers to exchange information on controlling
and eradicating trypanosomiasis in Africa.
    "Sleeping sickness is a double-pronged threat to health and well-being in
Africa, and we are honored to have the opportunity to share our exciting new
approach with those individuals from around the globe who are most committed
to finding solutions," said Mr. Bellenson. "Our drug program against sleeping
sickness is at an early stage, but it has already produced candidates that
preclinically demonstrate high efficacy at low doses and low toxicity in human
cells at a range of doses.  This is particularly exciting since no new anti-
trypanosomiasis compounds with low toxicity have been developed in the past 60
years.  We look forward to collaborating with a variety of organizations to
rapidly advance this program in both animals and humans."
    Upstream recently acquired access to innovative drug candidates designed
to treat tropical parasitic diseases.  In laboratory studies in vitro, these
compounds have demonstrated human and veterinary potential against several
major tropical parasitic diseases, including trypanosomiasis.  These
parasites, which belong to a family of protozoa species that include Chagas
disease and malaria, infect millions of individuals in sub-Saharan Africa.
Current treatments are toxic, ineffective, inconvenient and expensive.
    Sleeping sickness is especially problematic since it has a major negative
impact on both humans and cattle. The scope of the problem is illustrated by
the fact that a number of speakers at the ISCTRC meeting noted that animal
trypanosomiasis is a leading cause of rural malnutrition, poverty and overall
economic underdevelopment in the region.  Effective new veterinary drugs for
sleeping sickness are expected to significantly increase the production of
cattle throughout sub-Saharan Africa and accordingly represent a sizeable
potential market that is estimated to be at least 5-6 times the $50 million in
annual veterinary sales of today's inadequate drugs.
    Mr. Bellenson concluded, "Sleeping sickness takes an enormous personal,
social and economic toll on communities in the developing world, affecting
millions of individuals and also decimating the cattle herds that are an
integral part of rural economies.  Our work with the ISCTRC and affiliated
organizations represents the beginning of what we expect to be broad
collaborative efforts with a variety of public and private organizations to
ensure the timely and cost-effective advancement of our new drug candidates
addressing these urgent needs."
    The International Scientific Council for Trypanosomiasis Research and
Control (ISCTRC) conference is being held in Luanda, Angola from October 1-5,
2007.
    
    About African Sleeping Sickness (trypanosomiasis)
    
    Sleeping sickness is a parasitic disease in people and animals caused by
protozoa of the Trypanosomiasis genus and transmitted by the tsetse fly.
According to the WHO, the disease is endemic in regions of sub-Saharan Africa
covering 36 countries and 60 million people.  There are an estimated 300,000
new cases each year.  Early symptoms include anemia, endocrine, cardiac and
kidney disorders.  The symptoms of the second neurological phase give the
disease its name; besides confusion and reduced coordination, the sleep cycle
is profoundly disturbed.  Without treatment, the disease is fatal, with
progressive mental deterioration leading to coma and death.  Damage caused in
the neurological phase can be irreversible.  Available treatments are toxic
and require lengthy intravenous infusion and hospitalization.  Trypanosomiasis
also is a major source of serious illness in cattle and other livestock, which
is estimated to cost the economies of sub-Saharan Africa about $4.5 billion
annually from lost farm income and increased malnutrition.
    
    About Upstream Biosciences, Inc.
    
    Founded in 2004, Upstream Biosciences is an emerging leader in the
discovery and development of novel drugs for tropical parasitic diseases and
in the development of genetic diagnostics for cancer susceptibility and drug
response.  Upstream's innovative approach to drug discovery and its
proprietary data mining pipeline enable it to apply advanced computational
approaches to generating novel drug candidates and to locating and analyzing
the genetic variations important to disease progression and drug response. For
more information visit www.upstreambio.com.
    Notice Regarding Forward-Looking Statements:  This news release contains
"forward-looking statements", as that term is defined in Section 27A of the
United States Securities Act of 1933, as amended, and Section 21E of the
United States Securities Exchange Act of 1934, as amended. Statements in this
press release which are not purely historical are forward-looking statements
and include any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking statements include,
among others, the expectation and/or claim, as applicable, that: (i) the
Company intends to unveil promising new approaches to treating sleeping
sickness at the conference and highlight the Company's drug candidates that
may continue to demonstrate promising in vitro activity against sleeping
sickness and other parasitic diseases; (ii) the Company's drug program
continues to produce candidates that preclinically demonstrate high efficacy
at low doses and low toxicity in human cells at a range of doses; (iii) the
Company may collaborate with a variety of organizations to rapidly advance the
drug program in both animals and humans; (iv) the Company's compounds continue
to demonstrate human and veterinary potential against several major tropical
parasitic diseases; (v) the Company may continue to engage in collaborative
efforts with a variety of public and private organizations to ensure timely
and cost-effective advancement of new drug candidates; (vi) the Company may
continue to discover and develop novel drugs for tropical diseases and develop
genetic diagnostics for cancer susceptibility and drug response; (vii) the
Company's business may enable it to apply advanced computational approaches to
generating novel drug candidates and to locating and analyzing the genetic
variations important to disease progression and drug response.  Actual results
could differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others: (i) the risk that the
Company does not execute its business plan; (ii) the inability of the Company
to keep pace with technological advancements in the field of genetic
diagnostics and the treatment of tropical parasitic diseases; (iii) the
Company's inability to adequately protect its intellectual property or the
Company's inadvertent infringement of third party intellectual property; (iv)
the Company not being able to retain key employees; (v) competitors providing
better or cheaper products and technologies; (vi) markets for the Company's
products not developing as expected; (vii) the Company's inability to finance
its operations or growth; (viii) inability to obtain all necessary government
and regulatory approvals; (ix) the inability to effectively market and
commercialize the Company's technologies, including the establishment of
viable relationships with third parties; and (*) the conference not proceeding
as planned for any reason. These forward-looking statements are made as of the
date of this news release and the Company assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements. Although the
Company believes that the beliefs, plans, expectations and intentions
contained in this press release are reasonable, there can be no assurance
those beliefs, plans, expectations, or intentions will prove to be accurate.
Investors should consider all of the information set forth herein and should
also refer to the risk factors disclosed in the Company's periodic reports
filed from time-to-time with the Securities and Exchange Commission and
available at www.sec.gov.

    
    Contacts:
    Media/Corporate:                         Investors:
    GendeLLindheim BioCom Partners           Samantha Haynes
    Barbara Lindheim                         800-539-0289
    212 918-4650                             info@upstreambio.com
    




For further information:

For further information: Media-Corporate, Barbara Lindheim of 
GendeLLindheim BioCom Partners, +1-212-918-4650, or Investors, Samantha Haynes
 of Upstream Biosciences Inc., +1-800-539-0289, info@upstreambio.com Web Site:
http://www.upstreambio.com

Organization Profile

UPSTREAM BIOSCIENCES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890